Medical Condition News

RSS

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

EpiCept Corporation today announced that it has earned a $2 million milestone payment from Meda AB, for the first commercial shipment of Ceplene® (histamine dihydrochloride) to a major country in the European Union, as defined in the agreement.

4 May 2010

CalMHSA announces agreement with CDMH

The California Mental Health Services Authority (CalMHSA), a newly formed California joint powers authority (JPA) of counties focused on the efficient delivery of California mental health projects and programs, announced today it has entered into a contract with the California Department of Mental Health (CDMH) to provide program development, administrative oversight, and fiscal management services to county members and other program participants choosing to assign specifically named mental health funds to the joint powers authority.

4 May 2010

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Gaucher disease, a rare enzyme deficiency disorder, is one of many conditions with few approved treatment options for patients. In a study published online today in Blood, the journal of the American Society of Hematology, researchers present positive results of a Phase II clinical trial of eliglustat tartrate, an oral therapy in development to treat Gaucher disease.

4 May 2010

Broccoli component sulforaphane targets and kills breast cancer stem cells

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells -- the small number of cells that fuel a tumor's growth -- according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

4 May 2010

PTSD symptoms more common among childhood cancer survivors

Young adult survivors of childhood cancers are four times more likely to develop Post-Traumatic Stress Disorder (PTSD) than their control group siblings, a Childhood Cancer Survivors Study has found.

4 May 2010

Kidneys of healthy adults show signs of chronic mild injury that increase with age: Mayo Clinic

Mayo Clinic researchers have found that the kidneys of healthy adults show signs of chronic mild injury that increase with age. This damage is present even though the adults showed no clinical signs of kidney disease. The findings are reported in the current issue of the, Annals of Internal Medicine.

4 May 2010

Medtronic completes enrollment in first of two CURE-AF clinical trials

Medtronic, Inc., today announced completion of patient enrollment in the first of two studies in the company's CURE-AF (Concomitant Utilization of Radiofrequency Energy for Atrial Fibrillation) clinical trial.

4 May 2010

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

Par Pharmaceutical Companies, Inc. today announced that its generic division, Par Pharmaceutical, has entered into an exclusive licensing agreement with Glenmark Generics Limited and Glenmark Generics Inc., USA to market ezetimibe 10 mg tablets, the generic version of Merck & Co. Inc.'s Zetia, in the U.S. Zetia is a cholesterol modifying agent with annual U.S. sales of approximately $1.4 billion, according to IMS Health data.

4 May 2010

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

University of Florida researchers will receive $250,000 to study an inventive cell-transfer therapy to treat cortical dysplasia, a condition where the brain develops abnormally before birth, causing severe epilepsy in children and adults.

4 May 2010

Baxter Healthcare's COLLEAGUE infusion pumps to be recalled

Baxter Healthcare Corporation today announced that it will recall COLLEAGUE infusion pumps from the U.S. market pursuant to an order under its existing June 2006 consent decree with the U.S. Food and Drug Administration (FDA). Baxter will work with the FDA to ensure that the recall process provides customers appropriate alternatives for supporting patients' needs.

4 May 2010

Depressive symptoms after ACS associated with vascular brain changes

A new study published in the current issue of Psychotherapy and Psychosmatics has examined brain activity after a heart attack.This study provides the first evidence that persistent depressive symptoms after acute coronary syndrome are associated with vascular brain changes.

4 May 2010

Play-based intervention trial at Sydney University for children with ADHD

The Sydney University Faculty of Health Sciences is seeking participants for a new play-based intervention program which aims to assist children with ADHD to develop their social interactions.

4 May 2010

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

NIH awards UIC $10M grant to study health disparities among underserved, minority women with breast cancer

A $9.6 million grant from the National Institutes of Health has been awarded to the University of Illinois at Chicago to study access to care and health disparities among underserved and minority women with breast cancer in Chicago.

4 May 2010

Weight loss through caloric restriction and increase in physical activity improve symptoms of GERD

Gastroesophageal reflux disease (GERD) is a debilitating problem for sufferers -- heartburn, difficulty swallowing, chest pain and acid reflux. According to a Mayo Clinic study that will be presented at Digestive Disease Week (DDW) 2010 in New Orleans May 1-5, even moderate weight gain can exacerbate those symptoms, DDW is the largest international gathering of physicians and researcher in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

3 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful completion of the first-in-human clinical trial with Spiegelmer® NOX-A12.

3 May 2010

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

NexBio, Inc. announced today the initiation of a trial of DAS181 (Fludase®) in patients with the respiratory conditions asthma and bronchiectasis, being conducted by researchers with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This trial will examine the effects of DAS181 in subjects with well-controlled or stable pulmonary disease.

3 May 2010

Medical Condition News

EpiCept's first Ceplene commercial shipment to the EU triggers $2M milestone payment from Meda

CalMHSA announces agreement with CDMH

Researchers present positive results of Phase II clinical trial of eliglustat tartrate

Broccoli component sulforaphane targets and kills breast cancer stem cells

PTSD symptoms more common among childhood cancer survivors

Kidneys of healthy adults show signs of chronic mild injury that increase with age: Mayo Clinic

Medtronic completes enrollment in first of two CURE-AF clinical trials

Par Pharmaceutical signs exclusive licensing agreement with Glenmark to market ezetimibe in the U.S.

Researchers receive $250,000 to study inventive cell-transfer therapy to treat cortical dysplasia

Baxter Healthcare's COLLEAGUE infusion pumps to be recalled

Depressive symptoms after ACS associated with vascular brain changes

Play-based intervention trial at Sydney University for children with ADHD

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

NIH awards UIC $10M grant to study health disparities among underserved, minority women with breast cancer

Weight loss through caloric restriction and increase in physical activity improve symptoms of GERD

FDA issues advisory on prostate cancer drugs

NOXXON Pharma completes first-in-human clinical trial with Spiegelmer NOX-A12

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

NIAID researchers initiate trial of DAS181 in patients with asthma, bronchiectasis

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News